Information Provided By: 
Fly News Breaks for November 2, 2018
HRTX, PCRX
Nov 2, 2018 | 08:27 EDT
After Pacira reported that (PCRX) Exparel grew 23% year-over-year in Q3, and even showed growth quarter-over-quarter, Leerink analyst Ami Fadia believes the near-term trajectory for Exparel continues to look promising, but she still believes its growth could be pressured in later years due to competition from Heron Therapeutics' (HRTX) HTX-011. She raised her price target on Pacira shares to $46 from $44 to reflect her improved outlook on Exparel, but keeps a Market Perform rating on the shares.
News For PCRX;HRTX From the Last 2 Days
There are no results for your query PCRX;HRTX
